Over 70% of artificial intelligence (AI) users in clinical trials see measurable gains in study speed, data analytics brand Medidata has revealed. 

The findings come from a new global research report, ‘The State of AI In Clinical Trials: Today and Tomorrow’, which investigates how AI is redesigning the clinical development landscape. According to the report, 73% of AI users believe that AI integration in clinical trials met or surpassed their expectations, including 70% of users who confirmed improved data accuracy. 

The study also reveals that 56% of organisations have already adopted AI in some capacity, with 93% of AI-using companies employing it for data capture and data quality oversight. AI could also be effective at the front end of the trial process, with 83% of companies using it for patient population and cohort identification before clinical trial. 

“The industry has progressed beyond AI Proof of Concepts,” said Tom Doyle, Chief Technology Officer at Medidata. “Forward-looking organisations are now scaling AI in targeted, high-impact ways. 

“This report underscores how we can leverage AI’s potential to expedite the development of new therapies. We are proud to lead this transformation and, alongside our partners, to reimagine our platform and clinical research to create trials that are more efficient, insightful, and ultimately, more successful.” 

Bruno Quinney, Content Team, DDW